Posted inDermatology Pediatrics
Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial
The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.
